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r t i c l e i n f orticle history:
eceived 10 September 2012
ccepted 24 September 2012
vailable online 18 May 201359-year-old man with no medical history presented with
roductive cough and hemoptysis for two months. Low-
rade fever, fatigue and body weight loss were noted.
hysical examination disclosed crackles in both lungs and
achectic appearance. Blood examination revealed hypoal-
uminemia and generalized inﬂammation with a high
-reactive protein level. Chest radiography and computed
omography showed multiple cavities of various sizes and
egmental consolidations in both lungs with upper lobes
redominance (Fig. 1A and B). He was admitted under
he impression of pulmonary tuberculosis initially. Sputum
cid-fast stain and tuberculosis culture did not yield tuber-
ulosis bacilli. Sputum culture yielded Aspergillus fumigatus
ater and ultrasound-guided ﬁne-needle aspiration of a pul-
onary nodule showed hyphae consistent with Aspergillus
pp. Chronic pulmonary cavitary aspergillosis was diagnosed.
erial survey did not show evidence of immunodeﬁciency.
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Este é um artigo Open Access sob a licençaAfter a 6-month course of voriconazole therapy, both symp-
toms and images remarkably improved (Fig. 2) and body
weight increased. Longer duration of antifungal therapy is
indicated.
Aspergillosis is an illness caused by aspergillus organisms
with various manifestations. Chronic cavitary pulmonary
aspergillosis is a multicavitary disease in immunocompetent
patients and progresses over time. Previous mycobac-
terium infections, allergic bronchopulmonary aspergillosis
and chronic obstructive pulmonary disease are the most
common predisposing conditions.1 Most patients are often
suspected of having tuberculosis initially. The common symp-
toms include cough, shortness of breath, hemoptysis and
body weight loss. Radiographic examination usually disclosedInternal Medicine, Taichung Veterans General Hospital, No. 160,
multiple cavities of various sizes and ill-deﬁned regions
of consolidation, mainly in upper lungs. Diagnosis can be
made by classical clinical and radiographic presentations
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Fig. 1 – Chest radiography (A) and computed tomography
(B): multiple cavities of various sizes and segmental
Fig. 2 – Chest radiography after a 6-month course of
r
1
2
3consolidations, mainly in the upper lungs (arrows).combined with a positive aspergillus serology and/or cul-
ture of Aspergillus spp. from the lungs.2 Antifungal agents
are the mainstays of therapy. Lifelong therapy is often
required.3,4
4voriconazole therapy showing remarkable improvement.
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